Aktie 6547 MEDIGEN VACCINE BIOLOGICS CORPORATION
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Medigen Vaccine Biologics Corporation

Aktien

6547

TW0006547003

6547

Schlusskurs Taipei Exchange
Andere Börsenplätze
 00:00:00 19.04.2024 		% 5 Tage % 1. Jan.
48.5 TWD -3.39% Intraday Chart für Medigen Vaccine Biologics Corporation -6.91% -30.81%
15.03. Medigen Vaccine Biologics Corporation meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI
2023 Medigen Vaccine Biologics Corporation meldet die Ergebnisse für das dritte Quartal und die neun Monate bis zum 30. September 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Medigen Vaccine Biologics Corporation Reports Earnings Results for the Full Year Ended December 31, 2023
Medigen Vaccine Biologics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
WHO Initiative Signs New Licensing Agreements On Covid-19 Technologies [press release]
Medigen Vaccine Biologics Corporation Provides License Covid-19 Vaccine to WHO C-TAP and UN Medicines Patent Pool
Medigen Vaccine Biologics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Medigen Vaccine Biologics Corporation Withdraws Covid-19 Vaccine Provisional Application and Update with Three-Dose Data for Further Review
Medigen Vaccine Biologics Corporation Approves the Election of Ming-Yi ,Wu as Independent Director and Member of Audit and Remuneration Committees
Medigen Vaccine Biologics Corporation Files New Drug Application of MVC EV71 Vaccine to Drug Administration of Vietnam
Medigen Vaccine Biologics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023
Medigen Vaccine Biologics Corporation Reports Earnings Results for the Full Year Ended December 31, 2022
Medigen Vaccine Biologics Corporation Announces Board Changes
Medigen Vaccine Biologics Corporation Announces the Resignation of Chang, Ming-Cheng as Independent Director
Medigen Vaccine Biologics Corporation Receives the NDA Approval Letter of Mvcquadrivalent Influenza Vaccine from Taiwan Food and Drug Administration
Medigen Vaccine Biologics Corporation Announces Results of MVC COVID-19 Vaccine Phase 3 Clinical Trial in Thailand
Medigen Vaccine Biologics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Taiwan firm to provide free COVID-19 testing for Japan-bound visitors
Medigen Vaccine Biologics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Medigen Vaccine Biologics : Clarification on media reports
Medigen Vaccine Biologics : Announcement of the company's resolutions on the stock dividend ex-rights base date
Medigen Vaccine Biologics : Announcement of the Company's full receipt of cash capital increase in 2022 and the reference date of capital increase
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 6547 Aktie
  4. Nachrichten Medigen Vaccine Biologics Corporation
  5. Andere Sprachen